Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
In 1805, American inventor Oliver Evans described a closed vapor-compression refrigeration cycle for the production of ice by ether under vacuum. In 1820, the British scientist Michael Faraday liquefied ammonia and other gases by using high pressures and low temperatures, and in 1834, an American expatriate in Great Britain, Jacob Perkins, built the first working vapor-compression refrigeration system. It was a closed-cycle device that could operate continuously. A similar attempt was made in 1842, by American physician, John Gorrie, who built a working prototype, but it was a commercial failure. American engineer Alexander Twining took out a British patent in 1850 for a vapor compression system that used ether. The first practical vapor compression refrigeration system was built by James Harrison, a Scotsman. His 1856 patent was for a vapor compression system using ether, alcohol or ammonia. He built a mechanical ice-making machine in 1851 on the banks of the Barwon River at Rocky Point in Geelong, Victoria, and his first commercial ice-making machine followed in 1854. Harrison also introduced commercial vapor-compression refrigeration to breweries and meat packing houses, and by 1861, a dozen of his systems were in operation. The first gas absorption refrigeration system (compressor-less and powered by a heat-source) was developed by Edward Toussaint of France in 1859 and patented in 1860. It used gaseous ammonia dissolved in water ("aqua ammonia").
Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance. A 2026 systematic review on ADHD medication tolerance found evidence of tolerance developing to some affective state effects of amphetamine (e.g., positive mood and drug liking) within two weeks of daily use, but little to no evidence of long-term tolerance to its therapeutic or cardiovascular effects.
=== Mimicry === Much like the Salticidae family of spiders, P. phalangioides also use mimicry as a predatory tactic to subdue their prey; however, unlike jumping spiders, P. phalangioides do not rely on vision for predation. This mimicry consists of creating specialized vibrations to trick the prey into thinking that it has caught an insect or another spider. The prey then slowly approaches its supposed catch at which point the P. phalangioides spider raises up on its long legs. The spider patiently waits until the exact moment at which the prey touches one of its legs. Then, the P. phalangioides spider quickly immobilizes its prey by using its legs to wrap it up in layers of silk. Its long legs give it plenty of distance from the prey to avoid being bitten in retaliation. After immobilizing its prey, P. phalangioides can administer their venomous bite to the prey and consume it. Even forms of prey that do not fully make it onto the web of P. phalangioides are not safe. Often, prey will trip over the edges of the web, thus providing P. phalangioides with an optimal time to attack. P. phalangioides is capable of clinging onto their web with two of their legs while the rest of their body leans out of the web and shoots silk in the direction of the prey to subdue it.
== Commercialization == 1-MNA has been approved for use in food products in the form of 1-MNA chloride. The approval process in the European Union was successfully completed by PHARMENA SA. In 2017, the European Food Safety Authority (EFSA) confirmed the safety of 1-MNA chloride in food supplements, leading to its authorization in 2018 under EU Regulation 2018/1123. 1-MNA chloride is currently used in dietary supplements. Other chemical forms of 1-MNA are not currently allowed on the market as food.
Pennebaker), Grey Gardens (Albert and David Maysles), Titicut Follies (Frederick Wiseman), Primary and Crisis: Behind a Presidential Commitment (both produced by Robert Drew), Harlan County, USA (directed by Barbara Kopple), Lonely Boy (Wolf Koenig and Roman Kroitor) are all frequently deemed cinéma vérité films. The fundamentals of the style include following a person during a crisis with a moving, often handheld, camera to capture more personal reactions. There are no sit-down interviews, and the shooting ratio (the amount of film shot to the finished product) is very high, often reaching 80 to one. From there, editors find and sculpt the work into a film. The editors of the movement – such as Werner Nold, Charlotte Zwerin, Muffie Meyer, Susan Froemke, and Ellen Hovde – are often overlooked, but their input to the films was so vital that they were often given co-director credits. Famous cinéma vérité/direct cinema films include The Snowshoers (Les Raquetteurs), Showman, Salesman, Near Death, and The Children Were Watching.
Sources: en.wikipedia.org
In plants and some prokaryotes, glucose is a product of photosynthesis. Glucose is also formed by the breakdown of polymeric forms of glucose like glycogen (in animals and mushrooms) or starch (in plants). The cleavage of glycogen is termed glycogenolysis, the cleavage of starch is called starch degradation. The metabolic pathway that begins with molecules containing two to four carbon atoms (C) and ends in the glucose molecule containing six carbon atoms is called gluconeogenesis and occurs in all living organisms. The smaller starting materials are the result of other metabolic pathways. Ultimately almost all biomolecules come from the assimilation of carbon dioxide in plants and microbes during photosynthesis. The free energy of formation of α-d-glucose is 917.2 kilojoules per mole. In humans, gluconeogenesis occurs in the liver and kidney, but also in other cell types. In the liver about 150 g (5.3 oz) of glycogen are stored, in skeletal muscle about 250 g (8.8 oz). However, the glucose released in muscle cells upon cleavage of the glycogen can not be delivered to the circulation because glucose is phosphorylated by the hexokinase, and a glucose-6-phosphatase is not expressed to remove the phosphate group. Unlike for glucose, there is no transport protein for glucose-6-phosphate. Gluconeogenesis allows the organism to build up glucose from other metabolites, including lactate or certain amino acids, while consuming energy. The renal tubular cells can also produce glucose. Glucose also can be found outside of living organisms in the ambient environment.
The largest risk of relapse occurs within the first year post-discharge from eating disorder therapy treatment. Within the first two years post-discharge, approximately 31% of anorexia nervosa patients relapse. Many complications, both physical and psychological, improve or resolve with nutritional rehabilitation and adequate weight gain. Anorexia nervosa is estimated to occur in approximately 0.3–4.3% of women and 0.2–1% of men in Western countries at some point in their life. Levels in other countries are unclear due to undiagnosis and a lack of awareness, though it can be presumed it is more present in Western societies due to a higher focus on low body weight and beauty on social media and real life. There is an observation for an increase in the diagnosis of anorexia from the 20th century onwards: it is unclear whether this is due to an actual increase in its frequency or simply due to improved diagnostic capabilities. In 2013, it directly resulted in about 600 deaths globally, up from 400 deaths in 1990. Eating disorders also increase a person's risk of death from a wide range of other causes, including suicide. About 5% of people with anorexia die from complications over a ten-year period with medical complications and suicide being the primary and secondary causes of death respectively. Anorexia has one of the highest death rates among mental illnesses, second only to opioid overdoses.
Class AA ("Double-A") was established in 1912, as the new highest classification of Minor League Baseball. Previously, Class A had been the highest level, predating the establishment of the National Association of Professional Baseball Leagues—the formal name of Minor League Baseball—in 1901. Entering the 1912 season, three leagues were designated as Class AA:
== Description == Senna occidentalis is a foetid shrub that typically grows to a height of 1–2 m (3 ft 3 in – 6 ft 7 in) and has softly-hairy branches and stems. Its leaves are pinnate, 150–170 mm (5.9–6.7 in) long on a petiole 20–40 mm (0.79–1.57 in) long, with three to seven pairs of broadly elliptic to egg-shaped leaflets 50–70 mm (2.0–2.8 in) long and 30–40 mm (1.2–1.6 in) wide, spaced 15–30 mm (0.59–1.18 in) apart. There is a sessile glands near the base of the petiole. The flowers are yellow and arranged on the ends of branchlets and in upper leaf axils in groups of two to four on a peduncle 2–5 mm (0.079–0.197 in) long, each flower on a pedicel 10–15 mm (0.39–0.59 in) long. The petals are up to 10 mm (0.39 in) long and there are six fertile stamens, the anthers varying in length from 4 to 6 mm (0.16 to 0.24 in) long, and four staminodes. Flowering occurs all year, and the fruit is a cylindrical pod 120–180 mm (4.7–7.1 in) long, about 3 mm (0.12 in) wide and slightly curved.
There are two independent families of glutamic proteases (G1 and G2), and have a limited distribution. They were originally thought to be limited to filamentous fungi mainly in the Ascomycota phylum. Subsequently, however, glutamic proteases have been identified in bacteria and archaea. A glutamic protease from a plant virus (strawberry mottle virus) has also been identified. The first superfamily of glutamic proteases was identified in the fungi Scytalidium lignicola and Aspergillus niger var. macrosporus, from which scytalidoglutamic peptidase (eqolisin) and aspergilloglutamic peptidase are derived respectively. These two proteases contain active site Glu and Gln residues and are grouped under MEROPS family G1. A convergently evolved glutamic peptidase, the pre-neck appendage protein (bacteriophage phi-29), uses a Glu and Asp dyad at the active site, and is classified as MEROPS family G2.
Sources: en.wikipedia.org
=== Migraine prophylaxis === Candesartan may be helpful in migraine prevention as it has better tolerability and fewer side effects compared to other first line medications. It has been recommended by multiple guidelines for migraine prophylaxis in adults with different levels of recommendations, however further studies on larger populations are needed.
== Side effects == Seltorexant is reported to be safe and well-tolerated. Side effects of seltorexant observed in clinical trials so far have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares.
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development.
For a first-order reaction, the half-life of a reactant is independent of its initial concentration. Therefore, if the concentration of A at some arbitrary stage of the reaction is [A], then it will have fallen to 1/2[A] after a further interval of
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.